Since the 1960s, Japan has experienced a striking increase in the incidence of colorectal cancer, now the second most common cancer in the country. Meanwhile, the management of colorectal cancer has changed dramatically with the implementation of, for example, screening, endoscopy and adjuvant chemotherapy. It is therefore of interest to monitor the long-term trends in population 'cure' in Japan. We analysed 33 885 colorectal cancer cases diagnosed between 1975 and 2000 in Osaka. We applied the multivariable mixture cure model to estimate cure fraction and median survival time (MST) for 'uncured' patients, by sex, age, stage, period at diagnosis and subsite. For colon cancer, the cure fraction increased by about 25%, while MST for the uncured was prolonged from 8 to 12 months. The cure fraction was 5% higher in men than in women, while MST was similar in both. The cure fraction also increased for localized and regional tumours. For rectal cancer, the cure fraction increased by about 25 -30%, but remained lower than for colon cancer. From the late 1970s, the cure fraction for colorectal cancer increased dramatically due to better management of detection and care for colorectal cancer. This improvement was obtained at the cost of shorter MST for uncured patients.
BACKGROUND
As a result of a rapid increase in incidence for four decades since the mid-1960s, colorectal cancer has become one of the most common cancers in Japan (1,2). Colorectal cancer incidence in Japan is one of the highest worldwide (3) due to rapid diet transformations (4, 5) and colorectal cancer is a predominant public health burden. In the past three decades, there have been important changes in the management of colorectal cancer in Japan: a programme of mass screening by the faecal occult blood test was initiated in 1992, while several major improvements in treatment have also been implemented.
Prognosis for colorectal cancer has improved significantly in Japan, with 5-year survival at about 30% in the early 1970s and 55% in early 2000 (6) . However, this single indicator may be insufficient to completely and accurately reflect the numerous, important changes in managing colorectal cancer patients and to identify the remaining weaknesses. We aimed to assess the impact of these changes by monitoring the trends in population 'cure' of colorectal cancer in Osaka, Japan. The effect of age and tumour stage at diagnosis on these trends was also examined.
METHODS

DATA SOURCES
We analysed 21 032 colon (ICD-10 code: C18) and 12 757 rectal (C19 -C20) cancer cases diagnosed and registered in the population-based cancer registry of Osaka Prefecture between 1975 and 2000. The Osaka cancer registry regularly receives death certificates for patients resident in the Osaka Prefecture at the time of their death. Furthermore, the vital status of the patients who are known as still alive 5 and 10 years after diagnosis was checked using the city-level residence registries. Those cases diagnosed from 1975 to 1995 were followed up for 10 years after their diagnosis, whereas follow-up was limited to 5 years for those diagnosed from 1996 to 2000. We did not include patients of Osaka city (36%) in our analysis, because the vital status of patients in Osaka city diagnosed before 1993 was not recorded. A small proportion of cases were lost to follow-up, 2.2% of the patients diagnosed in 1975 -95 (10-year follow-up) and 1.2% of the patients diagnosed in 1996-2000 (5-year follow-up).
STATISTICAL ANALYSIS
CURE PARAMETERS
Within the relative survival framework, population cure is a statistical concept corresponding to the absence of excess mortality among cancer patients in comparison to a similar general population (7) . The mortality of this general population, the background mortality, is provided by life tables. Cure models assume that the cancer patients can be split into two groups: the 'cured' group and on top of that, the 'uncured' group for which relative survival function is estimated. Using separate calculations for men and women, and for colon and rectum, we estimated the cure fraction and median survival time (MST) for uncured cases, by the period of diagnosis (1975 -80, 1981 -85, 1986-90, 1991 -95 and 1996 -2000) , age at diagnosis (15 -49, 50 -59, 60 -69, 70 -79 and 80 -99), tumour stage at diagnosis (localized, regional and distant metastasis) and, for colon, subsite (left and right colon). We applied a multivariate mixture cure fraction model with a logit link and a Weibull distribution for the survival of the uncured patients. Both Weibull parameters (i.e. shape and scale parameters) were allowed to vary by period, age and stage at diagnosis since proportional excess hazards were unlikely for these variables (8) . Background mortality was provided by national life tables for Japan, defined by sex, single year of age and single calendar year.
MISSING DATA
Tumour stage data were missing for 10% of the colorectal cancer patients and subsite for about 25% of the colon cancer patients (Table 1) . Multiple imputation by chained equation (9) was applied to deal with this missing information. The imputation model consisted of multinomial logistic models containing, in addition to tumour stage and subsite (for colon), follow-up time, vital status, period and age at diagnosis, tumour morphology as well as interactions between follow-up time and age and stage. Ten 'completed' data sets were generated with imputed values for the cases with missing information for stage and subsite. Cure parameters were then estimated on the 10 completed data sets using Rubin's rules (10) .
Patients with missing stage data were more likely to be older and diagnosed in the earlier calendar periods, while there was very little variation with time among the proportion with missing subsite data (11) . The imputed stage was mostly regional metastasis in the early period and then shifted to the localized stage. The imputed subsite was a little more left-side colon. For older patients, survival time for patients missing stage or subsite data was shorter than patients with known stage or subsite.
All data management and analyses were carried out using Stata MP version 11.1 (12) .
RESULTS
During the study period, age at diagnosis of colorectal cancer increased. The proportion of patients with localized tumours increased until the mid-1990s while the proportion of both the regional and distant tumours decreased. The pattern of change seems to have reached a plateau in the late 1990s (Table 1) .
Although their levels differed in some ways, trends in both cure parameters were very similar for men and women, and for colon and rectum cancers (Tables 2 and 3 ; Supplementary Figs S1 and S2). Overall, both the cure fraction and the MST for uncured increased during the study period, with a dramatic improvement for the cure fraction. However, the MST for uncured shortened in the early (colon) or late (rectum) 1990s, while the cure fraction did not improve in the late 1990s. Among the patients diagnosed with colon cancer from 1996 to 2000, 62% of men and 58% of women were predicted to be cured of their cancer, with an MST for uncured of just below 1 year. For rectal cancer and both sexes, the cure fraction was about 57% with an MST of slightly less than 18 months.
The overall temporal trends by age group were very similar, with a dramatic increase in cure fraction across all age groups for both cancer sites and sexes. Overall, the cure fraction varied little with age until the age of 80 and over (Tables 2 and 3 ; Supplementary Figs S3 and S4). For the period 1996 -2000, if the MST for uncured reached 12 months or more (colon) and 18 months (rectum) for patients under 70 years old, it remained particularly short for the elderly, lower than 6 months (colon) or around 8 months (rectum).
Jpn J Clin Oncol 2012;42 (10) 975 For both colon and rectum cancer, the proportion of men and women cured from a local tumour rose steadily until the mid-1990s and reached a plateau over 85% (Tables 2 and 3 ; Supplementary Figs S5 and S6) . The improvement over the study period was also impressive among the patients diagnosed with a regional tumour since the cure fraction more or less doubled and between 46 (men, rectum) and 57% (men, colon) of these patients were cured. Although the cure fraction also increased among the patients with a metastatic tumour, less than 7% of these patients were cured from 1996 to 2000. Apart from the last period of diagnosis, the MST for uncured lengthened considerably for all tumour stages, including the distant. This pattern was however somewhat attenuated for women with colon cancer.
The temporal patterns of the cure fraction and the MST for uncured patients were similar for the left and right colon. However, cure parameters were higher for the left colon (Table 2) .
DISCUSSION
We observed a dramatic increase in cure fraction until the mid-1990s and a less noticeable lengthening of the MST for the uncured cases. All age groups and stage groups (with the exception of metastasis patients group) also showed a dramatic increase in cure fraction until the mid-1990s and then levelled-off. The overall increase in cure fraction might be due to both the shifting to a more favourable stage and the increase in age-and stage-specific cure fraction. Improvement in the management of colorectal cancer may also have played a role.
Distribution of age at diagnosis shifted considerably in the older groups from 1975 to 80 and 1996 to 2000: the under-50 age group, 22% of the patients in the first period represented less than 8% in the last period. However, trends in cure and MST for uncured were similar across all age groups. This explains why, after adjusting for other factors, age did not play a notable role in the observed improvements in cure parameters. At the same time, tumour stage at diagnosis shifted widely, mostly from regional to local stages and particularly until the mid-1990s. This shift is very likely to be related to the wider use of endoscopy to detect tumours at an earlier stage. While diagnostic endoscopy was used in less than 30% of colon cancer patients and less than 60% of rectal cancer patients in the late 1970s, the figures were around 80% in the late 1990s (13), an upper limit hard to exceed (Fig. 1) . The more tumours were detected at earlier stage, the more curative resections were possible, as shown by the parallel trends in the proportion of curative resections (Fig. 1) .
We have observed lower cure fraction in women, both overall and by age group, while stage-specific cure fractions were similar in both sexes. Women were diagnosed with more advanced stage than men (Table 1) . We observed similar pattern for stomach cancer (14) . Regular health monitoring is offered by large companies and for full-time workers, which means that women, more often part-time employees in small companies, may have fewer opportunities for earlier diagnosis than men.
These observations are good news and reflect a general improvement in the diagnosis and the treatment of these two cancers according to the interpretation of Verdecchia et al. (15) . However, the figures showed some divergences from that general pattern. From the 1990, both cure fraction and MST for uncured levelled off or slightly decreased. This pattern was mostly seen among the patients at the localized tumour stage. It might reflect a change in patients' characteristics, in particular in the localized tumour group because of the wider use of early detection method, smaller tumours 
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Cure by age and stage from colorectal cancer were found and were curatively resected. However, more in situ tumours were diagnosed and removed from the localized tumour group, leaving the 'more advanced' cases within the localized tumour group. Although only 20% of the target population in Osaka is covered by the mass-screening programme (16) , such a stage-shifting phenomenon is quite similar to what has been observed in cervical cancer in countries with high screening coverage, in which survival plateaued or even declined (17) . It may reflect the high use of opportunistic screening.
The cure fraction of colorectal cancer in Osaka was generally higher than in other countries. For example, in the EUROCARE study, the cure fraction ranged between 24.8 and 48.0% for patients diagnosed from 1988 to 99 (18) . This could be largely attributable to the differences in stage distribution. In Osaka, the advanced stage (distant metastasis) constituted 23% of colon cancer and 18.6% of rectal cancer from 1996 to 2000, whereas in Europe, the proportion of advanced stage for colorectal cancer ranged between 25% (France) and 37% (Poland) between 1996 and 1998 (19). (20) . It is striking that this shortening in MST occurred while the use of in particular chemotherapy dramatically decreased (Fig. 1) . Compared with analysis on data after imputation, the complete-case analysis showed slightly higher cure fractions and longer MST for uncured cases, especially among localized stage patients. Such over-estimations hardly modify the interpretation of our findings.
This study was implemented using population-based cancer registry data in Osaka. Compared with hospital series and hospital-based cancer registry data, the information available in our study was limited, which prevented us from evaluating the influence of type of treatment and detection method on the trends in cure parameters. However, in contrast to the clinical database, our study included all cancer cases within defined geographical areas, regardless of their age, co-morbidities or prognosis. Furthermore, our population-based results, among the highest cure fraction worldwide, show that since virtually all colorectal cancer patients are diagnosed by endoscopy and received surgical treatment with curative intent, any further progress in survival and cure is likely to require new, innovative strategies of colorectal cancer management.
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